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Abstract
Background: Triacylglyerol-rich very low density lipoprotein (VLDL) particles are the primary
carriers of fatty acids in the circulation and as such serve as a rich energy source for peripheral
tissues. Receptor-mediated uptake of these particles is dependent upon prior association with
apolipoprotein E (apoE-VLDL) and is brought about by cell surface heparan sulfate proteoglycans
(HSPG) in some cell types and by the low density lipoprotein receptor-related protein (LRP) in
others. Although LRP's role in apoE-VLDL uptake has been well studied, the identity of the HSPG
family member that mediates apoE-VLDL uptake has not been established. We investigated if
syndecan-1 (Syn-1), a transmembrane cell surface HSPG, is able to mediate the internalization of
apoE-VLDL and examined the relationship between Syn-1 and LRP toward apoE-VLDL uptake. For
this study, we used a human fibroblast cell line (GM00701) that expresses large amounts of LRP,
but possesses no LDL receptor activity to eliminate its contributions toward apoE-VLDL uptake.
Results: Although LRP in these cells is fully active as established by substantial α2macroglobulin
binding and internalization, uptake of apoE-VLDL is absent. Expression of human Syn-1 cDNA
restored apoE-VLDL binding and uptake by these cells. Competition for this uptake with an LRP
ligand-binding antagonist had little or no effect, whereas co-incubation with heparin abolished apoE-
VLDL internalization. Depleting Syn-1 expressing cells of K+, to block clathrin-mediated
endocytosis, showed no inhibition of Syn-1 internalization of apoE-VLDL. By contrast, treatment
of cells with nystatin to inhibit lipid raft function, prevented the uptake of apoE-VLDL by Syn-1.
Conclusion: These data demonstrate that Syn-1 is able to mediate apoE-VLDL uptake in human
fibroblasts with little or no contribution from LRP and that the endocytic path taken by Syn-1 is
clathrin-independent and relies upon lipid raft function. These data are consistent with previous
studies demonstrating Syn-1 association with lipid raft domains.
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Background
Fatty acids, triacylglycerols, and cholesterol in plasma
originate primarily from two sources; dietary intake and
that which is synthesized and secreted by hepatocytes.
Dietary lipids circulate in the form of chylomicrons which
are synthesized by intestinal epithelial cells. They are rela-
tively short lived particles during the postprandial period
as they are rapidly metabolized to remnant lipoproteins
and cleared from the circulation primarily by hepatocytes.
By contrast, the liver synthesizes triacylglycerol-rich lipo-
proteins in the form of very low density lipoprotein
(VLDL) particles which are much longer-lived fatty acid
carriers than remnant lipoproteins. Because of this, VLDL
particles provide the largest single source of fatty acids for
peripheral tissues found in the circulation. These fatty
acids are a rich energy source for cells with high metabolic
rates and are also stored by adipose tissue for mobiliza-
tion during periods of fasting. Previous studies have also
shown that VLDL is highly atherogenic since excessive
uptake of these lipoproteins by macrophages causes mas-
sive cholesterol accumulation and foam cell formation [1-
3]. Moreover, elevated levels of VLDL are found in the
plasma of patients with type III hyperlipoproteinemia [4].
It follows from these observations that cardiovascular
health requires controlled levels of VLDL particles in the
circulation, whether by decreased synthesis or increased
uptake.
Considerable evidence has been presented suggesting that
the mechanism for VLDL particle clearance involves cell
surface binding and endocytic activities of either heparan
sulfate proteoglycans (HSPG) [5-7] or the low density
lipoprotein receptor-related protein (LRP) [8,9], or both
receptors acting in a synergistic manner at the cell surface
[10]. Receptor-mediated association of VLDL with the cell
surface also requires enrichment of the particle with apol-
ipoprotein E (apoE) [6,11]. Evidence supporting a role for
LRP in apoE-VLDL uptake has been gathered by blocking
LRP's endocytic function with a ligand binding antagonist
or by tissue-specific gene ablation, both of which result in
increased circulating levels of VLDL particles [12,13].
HSPG-mediated internalization of apoE-VLDL has been
reported in several independent cell culture systems
including fibroblasts [14-16], CHO cells [17], HepG2
cells [18,19], macrophages [20], and vascular smooth
muscle cells [21]. In each of these cell types, a significant
reduction in apoE-VLDL internalization was demon-
strated following the inhibition of HSPG activity either
through a coincubation with heparin or heparinase treat-
ment prior to ligand binding. Moreover, intravenous
administration of heparinase into the portal circulation
reduced hepatocyte-mediated VLDL uptake by 70%
[7,10]. Notably, in contrast to the studies examining LRP's
role in apoE-VLDL clearance, studies on HSPG report that
a coincubation of labeled apoE-VLDL with an LRP ligand
binding antagonist showed minimal effects on lipopro-
tein uptake indicating little or no participation by this
receptor. These results have created controversy as to the
identity of the receptor used by VLDL particles for endo-
cytic clearance. To distinguish which path, HSPG or LRP,
serves as the primary uptake mechanism for apoE-VLDL,
we have recently re-examined apoE-VLDL endocytosis fol-
lowing the inhibition of HSPG maturation using reagents
that prevent glycosaminoglycan chain addition [16]. In
this study, we showed that apoE-VLDL uptake occurs pri-
marily through an HSPG-mediated process with little or
no contributions from LRP.
Identifying the HSPG that mediates apoE-VLDL clearance
has been elusive. Specific HSPG, like those of the synde-
can [22,23], glypican [23,24] and perlecan [25,26] fami-
lies, have primarily been studied in the context of their
abilities to modulate growth factor responses. Although,
syndecan [27,28] and perlecan [29,30] have been shown
to internalize modified LDL, little information is available
identifying the HSPG responsible for apoE-VLDL uptake.
Syndecan-1 (Syn-1) was recently shown to colocalize with
chylomicron remnants at the surface of hepatocytes sug-
gesting that it may participate in the endocytic clearance
of dietary lipids [31]. In the present study, we investigated
if Syn-1 is capable of mediating apoE-VLDL uptake and
examined its functional relationship with LRP in lipopro-
tein handling at the cell surface.
Results
To determine if Syn-1 is capable of endocytic uptake of
apoE-VLDL and to examine the relationship between Syn-
1 and LRP toward apoE-VLDL clearance, we searched for a
cell line that 1) expresses no detectable Syn-1 to permit
transfection studies with human Syn-1, 2) expresses high
levels of LRP to permit accurate and reliable measure-
ments of its endocytic properties, and 3) expresses no LDL
receptor activity to remove its contribution toward apoE-
VLDL binding and clearance that might complicate our
measurements of Syn-1 and LRP activities. Our search led
us to the GM00701 human cell line which was obtained
from a patient diagnosed with familial hypercholestero-
lemia and expresses LDL receptors with < 1% of normal
activity. We compared LRP expression in this cell line to
other cell lines known to express this receptor, including
human SH-SY5Y neuroblastoma [32], mouse pre-adi-
pocyte 3T3-L1 [33] and human HT1080 fibrosarcoma
[34]. By semi-quantitative immunoblot analysis, we
found that the GM00701 cells express more LRP than
other cultured cells previously used to study LRP's cellular
activities (Fig. 1). Interestingly, the relative molecular
mass of LRP's light chain (~95 kDa) is slightly smaller in
the cultured cell lines as compared to liver tissue, which is
the in vivo location for the highest level of LRP expression.
This is likely due to post-translational processing since noLipids in Health and Disease 2006, 5:23 http://www.lipidworld.com/content/5/1/23
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alternatively spliced transcripts for LRP have been
reported.
Since GM00701 cells express large amounts of LRP, we
anticipated that they would have a substantial capacity to
bind and degrade the LRP specific ligand, α2-macroglobu-
lin (α2M). To test this assumption, GM00701 cells were
incubated at 4°C with 125I-α2M in the absence or presence
of unlabeled α2M or the LRP ligand binding antagonist,
receptor associated protein (RAP). A significant amount of
α2M bound to GM00701 cells (Fig. 2A), of which 80–90%
was specific as determined by competition with unlabeled
α2M and RAP. When the same experiment was performed
at 37°C to measure LRP-specific ligand internalization
and degradation, we found that GM00701 cells degraded
more 125I-α2M than the binding capacity at the cell surface
suggesting not only efficient LRP internalization, but also
rapid recycling (Fig. 2B).
Since LRP has previously been reported to bind apoE-
VLDL particles [8,9], we investigated if GM00701 cells
were able to efficiently bind 125I-apoE-VLDL with its high
expression level of LRP. To accomplish this, we isolated
VLDL particles from plasma obtained from New Zealand
White rabbits maintained on a high fat, high cholesterol
diet. Prior to radiolabeling, the VLDL preparation was
analyzed by SDS-PAGE followed by Coomassie staining
to confirm that these particles contain the expected apoli-
poproteins, B100 and E. As shown in Figure 2C (inset),
the purified VLDL particles do indeed contain apoB100
(Mr, 512 kD) and apoE (Mr, 34 kD) indicating that they
have the proper associated proteins necessary for efficient
receptor binding and internalization. When GM00701
cells were incubated at 4°C with 125I-apoE-VLDL, we
found little or no specific binding (Fig. 2C) indicating that
these cells are incapable of binding apoE-VLDL in spite of
the presence of endocytically active LRP. Cell surface
binding activity of our 125I-apoE-VLDL preparation was
confirmed by high level specific binding to mouse pre-
adipocyte 3T3-L1 cells [35].
The inability of GM00701 fibroblasts to bind 125I-apoE-
VLDL and the lack of Syn-1 expression as determined by
immunoblot and RT-PCR analysis (data not shown),
established these cells as a viable model for us to investi-
gate the functional relationship between Syn-1 and LRP
toward apoE-VLDL binding and clearance. Toward this
end, we constructed a mammalian expression vector con-
taining the full length human Syn-1 cDNA (pMH/Syn-1-
HA) and carried out transient transfection studies with
GM00701 cells. Immunoblot analysis of cells transfected
with vector alone (Fig. 3A, lane 1) showed no endogenous
expression of Syn-1. By contrast, cells transfected with
pMH/Syn-1-HA (lane 2) demonstrated efficient Syn-1
expression (Mr ~77kDa). The 77 kDa protein identified
by immunoblotting represents the core protein of Syn-1
[36,37]. Mature Syn-1 demonstrates a relative molecular
mass of > 250 kD as a result of its multiple gly-
cosaminoglycan additions [38].
In order to confirm proper maturation of Syn-1 in trans-
fected cells as defined by heparan sulfate glycosaminogly-
can addition, we transfected GM00701 cells with pMH/
Comparison of LRP expression in various cell lines Figure 1
Comparison of LRP expression in various cell lines. 
(A) Cell lysates were prepared using 1% Triton X-100 deter-
gent, proteins (20 µg/lane) were separated by 6% SDS-PAGE, 
and immunoblotted with anti-LRP pAb raised against a syn-
thetic peptide derived from the cytoplasmic tail sequence 
[59]. Bound antibodies were detected by chemiluminescence 
imaging. Rat liver extract was used as a positive control for 
LRP expression. (B) Densitometric scans of the 95 kD light 
chain of LRP in (A).
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Syn-1-HA vector and enriched for those cells stably
expressing Syn-1 using antibiotic selection. We then
immunoblotted protein extracts from GM00701/Syn-1-
HA cells prepared with 8 M urea. Urea extraction is often
necessary to release mature Syn-1 from cytoskeletal inter-
actions that are resistant to mild detergents such as Triton
X-100 [37,39]. As shown in Figure 3B, a high molecular
mass protein (Mr, > 250 kD) was identified by anti-Syn-1
antibodies following urea extraction (lane 2), but not
after extraction with Triton X-100 (lane 3). As expected,
treatment with Tris-buffered saline was unable to extract
Syn-1 from cells (lane 1) since Syn-1 is an integral mem-
brane protein.
To verify that the large molecular mass change in Syn-1 as
seen by immunoblotting is due to heparan sulfate gly-
cosaminoglycan addition, we investigated the effect of
heparinase treatment on the electrophoretic mobility of
Syn-1 from GM00701/Syn-1-HA cells. Without hepari-
nase treatment, mature Syn-1 migrated to its expected rel-
ative molecular mass of > 250 kDa (Fig. 3C, lane 1). With
heparinase treatment, a significant increase in Syn-1 core
protein (Mr, 77 kDa) was observed that directly corre-
sponded to a decrease in mature Syn-1 (Mr, > 250 kDa)
(lane 2). We interpret these data to indicate that mature
Syn-1 expressed by GM00701/Syn-1-HA cells contains
heparan sulfate glycosaminoglycan chains and undergoes
normal post-translational modifications.
Since GM00701 cells are unable to bind apoE-VLDL even
with high expression levels of LRP, we next asked if intro-
ducing Syn-1 expression is able to rescue apoE-VLDL
uptake by these cells. To address this, GM00701 and
GM00701/Syn-1-HA cells were incubated with DiI-
labeled apoE-VLDL at 37°C and examined by fluores-
cence microscopy for uptake of the labeled ligand. Con-
sistent with the results we obtained in 4°C binding
studies with 125I-apoE-VLDL, GM00701 cells were unable
to bind or internalize DiI-apoE-VLDL (Fig. 4, panel C).
However, GM00701/Syn-1-HA cells were able to readily
take up DiI-apoE-VLDL as evidenced by labeled apoE-
VLDL within intracellular vesicles (Fig. 4, panel D). These
data clearly show that expression of Syn-1 rescues apoE-
VLDL internalization by these cells. To measure the
increase in apoE-VLDL binding resulting from Syn-1
expression, we incubated GM00701 and GM00701/Syn-
1-HA cells with 125I-apoE-VLDL at 4°C in the absence or
presence of unlabeled apoE-VLDL and quantitated spe-
cific ligand binding. Expression of Syn-1 in GM00701/
Syn-1-HA cells resulted in a 5-fold increase in specific
apoE-VLDL binding as compared to control GM00701
cells (Fig. 5).
The question that arises from these observations asks if
LRP plays a role with Syn-1 in the binding and uptake of
125I-α2M and 125I-apoE-VLDL handling by GM00701 cells Figure 2
125I-α2M and 125I-apoE-VLDL handling by GM00701 
cells. GM00701 cells were incubated with 125I-α2M (1 µg/ml) 
at 4°C for 3 h (A) or at 37°C for 1 h (B) in the absence or 
presence of recombinant human RAP-GST (50 µg/ml) or 
unlabeled α2M (10 µg/ml). (C) GM00701 and 3T3-L1 cells 
were incubated with 125I-apoE-VLDL (2 µg/ml) supplemented 
with 3 µg/ml apoE at 4°C for 3 h in the absence (solid bars) 
or presence (shaded bars) of unlabeled apoE-VLDL (100 µg/
ml). After the indicated incubation time, 125I-ligand bound to 
cells at 4°C was quantitated by scintillation counting follow-
ing extraction of cells with 0.1 M NaOH. 125I-α2M degrada-
tion was quantitated following TCA precipitation as 
described in Methods. Error bars represent standard devia-
tions of triplicate points. Inset, purified VLDL was separated 
by 7.5% SDS-PAGE and proteins were stained with Coomas-
sie R. Molecular mass markers shown at left are in kD.
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apoE-VLDL. To address this question, we incubated
GM00701/Syn-1-HA cells with DiI-apoE-VLDL in the
absence or presence of either RAP-GST (to block LRP func-
tion) or heparin (to block Syn-1 function) and visualized
ligand uptake by fluorescence microscopy following a
37°C incubation. RAP is known to prevent the binding of
all ligands to LRP [40], including VLDL [41], and has
proven invaluable as a pharmacological antagonist for
characterizing LRP's ligand binding and uptake proper-
ties. With no co-incubation by ligand binding antago-
nists, DiI-apoE-VLDL is readily taken up by GM00701/
Syn-1-HA cells as was originally identified in Fig. 4 (Fig. 6,
Expression of syndecan-1 in GM00701 cells Figure 3
Expression of syndecan-1 in GM00701 cells. (A) GM00701 cells were transfected with pMH alone (lane 1) or pMH/Syn-1-
HA (lane 2). Forty eight hours after transfection, total protein was extracted from cells with 1% Triton X-100 and equal 
amounts of protein (20 µg/lane) were separated by 7.5% SDS-PAGE, transferred to PVDF membrane and immunoblotted with 
anti-Syn-1 polyclonal antisera (1:1000) that was raised against a recombinant his-tagged fusion protein representing full length 
human Syn-1. Chemiluminescence detection was used to visualize bound antibodies. (B) GM00701 cells were transfected with 
pMH/Syn-1-HA and cells were selected that stably express Syn-1 (GM00701/Syn-1-HA). Cells were incubated with either TBS 
(lane 1), 8 M urea (lane 2), or 1% Triton X-100 (lane 3). Insoluble material was pelleted by centrifugation and soluble proteins 
were separated by 7.5% SDS-PAGE and immunoblotted with anti-Syn-1 antisera as described in (A). (C) GM00701/Syn-1-HA 
cells were incubated without (lane 1) or with (lane 2) heparinase (1 unit/ml) for 5 h at 37°C. Total cellular proteins were 
extracted with 8 M urea, separated by 6% SDS-PAGE and immunoblotted with anti-Syn-1 antisera as described in (A). Aster-
isks indicate the 77 kD, non-glycosylated Syn-1 core protein [36, 37].
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panel A). Co-incubation with heparin blocked most, if
not all, DiI-apoE-VLDL uptake (Fig. 6, panel C) demon-
strating the requirement for heparan sulfate gly-
cosaminoglycans on Syn-1 for DiI-apoE-VLDL uptake.
However, RAP-GST demonstrated only marginal inhibi-
tion of uptake (Fig. 6, panel B), suggesting that Syn-1 is
necessary for apoE-VLDL uptake and is able to internalize
apoE-VLDL independent from LRP's endocytic activity.
We [16] and others [14,18-21] have previously shown
that internalization of apoE-VLDL by cells is partially
mediated by HSPG and in the present study we show that
Syn-1 is capable of serving the role of this HSPG. These
data now raise important questions as to the endocytic
pathway used for internalization. LRP, like other mem-
bers of the LDL receptor family, contains the clathrin-
mediated internalization signal, NPXY amino acid
sequence in their cytoplasmic tails. However, transmem-
brane HSPG such as Syn-1 do not contain this sequence
and are likely internalized by cells through a non-clathrin
mediated pathway. Previous studies have shown that anti-
body induced clustering of cell surface Syn-1 promotes its
association with detergent-insoluble lipid rafts [28]. In
addition, cholesterol depletion of cells prevented Syn-1
Expression of Syn-1 restores apoE-VLDL uptake in GM00701 cells Figure 4
Expression of Syn-1 restores apoE-VLDL uptake in GM00701 cells. GM00701 (panels A and C) and GM00701/Syn-1-
HA (panels B and D) cells were incubated with DiI-labeled apoE-VLDL (4 µg/ml) for 3 h at 37°C. Unassociated ligand was 
removed by rinsing, cells were fixed with paraformaldehyde and observed by fluorescence microscopy (panels C and D, 550 
nm excitation-573 nm emission). Corresponding phase contrast images are shown in panels A and B. Magnification, 630X.Lipids in Health and Disease 2006, 5:23 http://www.lipidworld.com/content/5/1/23
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from associating with these lipid rafts. Together, these
observations suggest a role for non-clathrin-mediated
pathways for Syn-1 internalization. To examine the path-
way taken by Syn-1 for the internalization of apoE-VLDL,
we measured uptake of 125I-apoE-VLDL and 125I-α2M by
GM00701/Syn-1-HA cells under conditions of K+ deple-
tion. Larkin, et al., have previously shown that K+ deple-
tion specifically inhibits clathrin-mediated
internalization, but has little or no affect on non-clathrin
mediated endocytosis [42]. As shown in Figure 7, K+
depletion significantly inhibited 125I-α2M uptake by LRP
as expected since LRP endocytosis is clathrin-mediated.
However, 125I-apoE-VLDL internalization was unaffected
by this treatment indicating that Syn-1 with bound apoE-
VLDL is endocytosed through a non-clathrin mediated
pathway.
To determine if Syn-1 with bound apoE-VLDL internalizes
through lipid raft domains, we examined the effect of nys-
tatin on uptake of DiI-apoE-VLDL in GM00701/Syn-1-HA
cells. Nystatin is a sterol-binding antibiotic that sequesters
membrane-associated cholesterol thereby disrupting
plasma membrane microdomains such as lipid rafts [43-
45]. As shown in Figure 8, nystatin had no effect on clath-
rin-mediated endocytosis of a2M (lower panels). By con-
trast, little or no uptake of DiI-apoE-VLDL occurred in the
presence of nystatin (upper panels) indicating that Syn-1
internalizes apoE-VLDL through a lipid raft microdo-
main.
Discussion
Our previous study demonstrated that HSPG are able to
bind and internalize apoE-VLDL with little or no contri-
butions from LRP [16]. In the present study, we now
explore if Syn-1 represents a class of HSPG that is able to
provide a path for apoE-VLDL binding and internaliza-
tion, and investigate its relationship with LRP in this func-
tion. Using GM00701 cells, a human fibroblast cell line
that expresses abundant amounts of LRP and no detecta-
ble Syn-1, we show that these cells are unable to bind or
internalize apoE-VLDL even with active LRP receptor
function, which was confirmed by α2M binding and deg-
radation. However, apoE-VLDL binding and internaliza-
tion by these cells was rescued following the introduction
of stable Syn-1 expression indicating that this HSPG is
fully capable of mediating lipoprotein binding and
uptake. We also show that apoE-VLDL internalization by
the transfected cells is blocked by heparin co-incubation,
but unaffected by a LRP ligand binding antagonist dem-
onstrating that Syn-1 mediates uptake in an LRP-inde-
pendent manner. To the best of our knowledge, this is the
first example of a member of the syndecan family of
HSPG serving as a clearance receptor for apoE-VLDL par-
ticles.
A previous study by Fuki, et al. [27], demonstrated that
Syn-1 internalizes lipoprotein lipase-enriched LDL
through a pathway that is distinct from clathrin coated
pits and that internalization proceeds after clustering Syn-
1 with a multivalent ligand. Since LRP apparently plays lit-
tle role in the uptake of apoE-VLDL in GM00701 cells, we
examined if internalization of apoE-VLDL by Syn-1 occurs
through a clathrin-dependent or clathrin-independent
pathway. We found that K+ depletion significantly inhib-
ited α2M uptake, which internalizes via LRP through a
clathrin-mediated pathway, but uptake of apoE-VLDL was
unaffected by this treatment. By contrast, treatment of
cells with nystatin, which disrupts lipid raft function [43-
45], prevented apoE-VLDL uptake by Syn-1 indicating
that Syn-1-mediated clearance of apoE-VLDL proceeds
through a non-clathrin pathway. This conclusion is also
consistent with the fact that the cytoplasmic tail of Syn-1
does not contain the clathrin-mediated internalization
signal sequence (NPXY). Additional evidence for non-
clathrin-mediated internalization for Syn-1 was obtained
through studies using a chimeric receptor consisting of the
ectodomain of the Fc receptor Ia linked to the transmem-
brane and cytoplasmic domains of Syn-1 [28]. Upon clus-
tering this chimera with IgG, it was found to redistribute
into detergent insoluble lipid rafts. Pretreatment of cells
with cholesterol depleting reagents prevented detergent
Comparison of 125I-apoE-VLDL binding to GM00701 and  GM00701/Syn-1-HA Figure 5
Comparison of 125I-apoE-VLDL binding to GM00701 
and GM00701/Syn-1-HA. GM00701 or GM00701/Syn-HA 
cells were incubated with 125I-apoE-VLDL (2 µg/ml) for 3 h at 
4°C in the absence or presence of unlabeled apoE-VLDL 
(100 µg/ml). Unbound ligand was removed by rinsing, cells 
were solubilized with 0.1 M NaOH and subjected to scintilla-
tion counting. Values shown represent specific 125I-apoE-
VLDL binding and were obtained by subtracting amounts of 
125I-apoE-VLDL bound in the presence of unlabeled apoE-
VLDL from total 125I-apoE-VLDL binding. Error bars repre-
sent standard deviations of triplicate points.
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insolubility of the Fc-Syn-1 chimera upon clustering and
inhibited its internalization. From these data it appears
that the transmembrane domain and cytoplasmic tail
sequences of Syn-1 are sufficient for partitioning the
receptor into lipid raft domains. Recently, it was shown
that Syn-4 also redistributes into lipid rafts upon cluster-
ing [46], suggesting that this may be a conserved feature
among all members of the syndecan family.
The mechanism of endocytosis by means of lipid raft
domains remains a topic of ongoing study; however,
information is becoming available as to the initial parti-
tioning of proteins into lipid rafts [47,48]. Possible mech-
anisms to segregate plasma membrane proteins include
hydrophobic modifications, such as lipidation, protein-
protein interactions with lipid-raft resident proteins, or
targeting signals that are encoded within the polypeptide
domain of the membrane protein. Although Syn-1 has
not been reported to undergo lipid modification or
directly interact with lipid raft residents, such as caveolin,
annexin, or flotillin, it may utilize intrinsic targeting infor-
mation within its transmembrane domain or cytoplasmic
tail in a similar fashion as the epidermal growth factor
receptor [49]. Once receptors internalize with their bound
ligand through non-clathrin mediated pathways, they can
deliver their cargo to classic endocytic compartments,
Heparin, but not RAP-GST, competes for DiI-apoE-VLDL uptake by GM00701/Syn-1-HA cells Figure 6
Heparin, but not RAP-GST, competes for DiI-apoE-VLDL uptake by GM00701/Syn-1-HA cells. GM00701/Syn-1-
HA cells were cultured on glass coverslips and incubated with DiI-labeled apoE-VLDL (4 µg/ml) in the absence (panel A) or 
presence of recombinant human RAP-GST (50 µg/ml, panel B) or heparin (200 µg/ml, panel C) at 37°C for 3 h. Cells were 
fixed and processed for fluorescence microscopy. Magnification, 630X.
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such as recycling endosomes [50]. As a result of this cross-
talk between non-clathrin pathways and classical endo-
cytic pathways, Syn-1 would be able to deliver apoE-VLDL
to lysosomal acid lipases for release of fatty acids for cel-
lular utilization [51]. Whether Syn-1 recycles to the cell
surface after delivering its cargo to endosomes remains to
be determined.
LRP was originally identified as a lipoprotein clearance
receptor by virtue of its structural homology with the LDL
receptor, its high level expression in liver and its function
in hepatic remnant metabolism elegantly demonstrated
using genetically modified mice [12,13]. However, the
question remains as to why in certain cell types, HSPG,
and as we show here, Syn-1, serves as the primary clear-
ance receptor for apoE-VLDL and LRP plays little or no
role in the uptake of this ligand. Answers to this question
may come from more recent studies investigating alterna-
tive functions for LRP (reviewed in [52-54]). LRP is now
known to carry out dual roles; serving as an endocytic
receptor for many diverse, structurally different ligands
and as a signaling receptor that is able to modulate activi-
ties of other cell surface proteins. Whether LRP functions
as a cargo receptor or signaling receptor may be deter-
mined by the state of receptor phosphorylation, post-
translational processing, or complement of cytosolic mes-
sengers/adaptors that might dictate the preference
between these dual functions. Thus, studies on hepato-
125I-α2M internalization, but not 125I-apoE-VLDL, is inhibited by K+ depletion of cells Figure 7
125I-α2M internalization, but not 125I-apoE-VLDL, is inhibited by K+ depletion of cells. GM00701/Syn-1-HA cells 
were treated with K+-depleted buffers (open symbols), or K+-containing serum-free media (closed symbols), as described in 
Methods. Cells were incubated with either 125I-apoE-VLDL (2 µg/ml) (circles) or 125I-α2M (0.5 µg/ml) (triangles) for 20 min at 
37°C. Specificity of uptake was determined by a parallel incubation with either unlabeled apoE-VLDL (100 µg/ml) or unlabeled 
α2M (5 µg/ml), respectively. After the 37°C incubation, cells were chilled to 4°C and acid stripped with 50 mM glycine, pH 3, 
100 mM NaCl for 5 min to remove surface bound ligand (that which was not internalized). Internalized ligand was quantitated 
by solubilizing cells with 0.1 N NaOH and scintillation counting.
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cytes have demonstrated that LRP functions as a key ele-
ment in lipoprotein handling in vivo, whereas in
fibroblasts [55,56] or cells of neuronal lineage [57], LRP
may be acting primarily as a co-receptor modulating sig-
nal transduction events that control cell behavior.
Methods
Materials
Human  α2-macroglobulin (α2M), heparin, and hepari-
nase were purchased from Sigma-Aldrich (St. Louis, MO).
Na125I was purchased from Perkin-Elmer (Boston, MA).
Pre-cast polyacrylamide electrophoresis (PAGE) gels and
goat anti-rabbit horseradish peroxidase-conjugated sec-
ondary antibody were from BioRad (Hercules, CA). All
oligonucleotide primers were synthesized by Integrated
DNA Technologies (Coralville, IA). All restriction
enzymes were from New England Biolabs (Ipswich, MA).
RAP-GST fusion protein was purified as previously
described [58]. Anti-LRP polyclonal antibody was raised
against an 18 amino acid peptide from the cytoplasmic
tail of human LRP [59]. Tissue culture plastics were pur-
chased from Corning (Corning, NY). Buffers, salts, and
detergents were obtained from either Sigma-Aldrich or
Calbiochem (La Jolla, CA).
Cell culture
GM00701 human fibroblasts (Coriell Institute, Camden,
NJ) were obtained from a patient diagnosed with familial
Syn-1 internalizes DiI-apoE-VLDL through a lipid raft-mediated pathway Figure 8
Syn-1 internalizes DiI-apoE-VLDL through a lipid raft-mediated pathway. GM00701/Syn-1-HA cells were incubated 
at 37°C in the absence or presence of nystatin (25 µg/ml) for 30 min prior to a 60 min incubation with DiI-apoE-VLDL (upper 
panels) or 488-α2M (lower panels) (5 µg/ml). Cells were fixed and visualized by fluorescence microscopy (488-α2M, FITC filter 
set; DiI-apoE-VLDL, rhodamine filter set). Magnification, 630X.
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hypercholesterolemia. This cell line expresses < 1% of
normal activity for the LDL receptor. GM00701 cells were
cultured in Minimal Essential Media, Eagle modification
with Earle's balanced salt solution (MEM-Eagle's, Life
Technologies/Invitrogen, Carlsbad, CA). Media was sup-
plemented with 2X concentration of essential and non-
essential amino acids and vitamins, 15% (v/v) fetal
bovine serum (Irvine Scientific, Santa Ana, CA), 100 µg/
ml streptomycin sulfate, and 100 units/ml penicillin G.
3T3-L1 cells were obtained from American Type Culture
Collection (Manassas, VA) and grown in Dulbecco's mod-
ified Eagle's medium (DMEM) (Invitrogen, Carlsbad, CA)
supplemented with 10% (v/v) fetal calf serum (Irvine Sci-
entific, Santa Ana, CA), 1 mM sodium pyruvate, 100 µg/
ml streptomycin sulfate, and 100 units/ml penicillin.
Cells were cultured at 37°C with 5% CO2 for GM00701
cells and 10% CO2 for preadipocyte 3T3-L1 cells. Cells
were passaged twice weekly.
Immunoblotting
Cell lysates were prepared with 20 mM Tris pH 7.4, 150
mM NaCl (TBS) containing either 1% (v/v) Triton-X100
or 8 M urea. Solubilized proteins were mixed with SDS-
PAGE sample buffer supplemented with 2% (v/v) β-mer-
captoethanol, heated to 95°C, separated by SDS-PAGE
and transferred to Immobilon-P (Millipore, Billerica, MA)
using a wet tank transfer system (BioRad, Hercules, CA).
Membranes were blocked with TBS, 0.1% (v/v) Tween-20,
5% (w/v) non-fat dry milk for 20 minutes at 23°C and
incubated with the indicated primary antibody for 2 h at
23°C. Membranes were washed three times (10 min each)
with TBS, 0.1% (v/v) Tween-20, and bound antibodies
were detected with species-specific HRP-conjugated sec-
ondary antibodies (1:3000, BioRad) followed by chemi-
luminescence detection according to the manufacturer's
instructions (Pierce, Rockford, IL). Images were captured
using a Syngene GeneGnome system equipped with a Pel-
tier-cooled 16-bit CCD camera and saturation detection.
Densitometry of scanned images was performed using
Scion Image software version 4.0.2.
Activation of α2-macroglobulin and labeling procedures
α2M was activated for receptor binding by incubating with
an equal volume of 0.4 M methylamine in 0.1 M Tris-HCl,
pH 8, for 2 h at room temperature. Unbound methyl-
amine was then removed by passage over a desalting col-
umn (PD-10, Amersham Biosciences). For
radioiodinations, both apoE-VLDL and α2M were labeled
with 125I (Perkin-Elmer) using Iodo-Beads (Pierce) as pre-
viously described [60]. Specific activities were routinely
between 3000 and 5000 cpm/ng protein. Using the Bligh-
Dyer lipid extraction procedure, we determined that
approximately 10% of 125I-label was incorporated into
lipid of the VLDL particle while the remaining 90% of
label was found coupled to protein. α2M was labeled for
fluorescence detection using Alexa Fluor®  488 Protein
labeling kit (Molecular Probes, Eugene, OR).
Cell surface 4°C binding assay
Cells were grown on tissue culture plates precoated with
1% gelatin and used when confluent. Cells were rinsed
twice with 20 mM Hepes, pH 7.4, 150 mM NaCl, 2 mM
CaCl2 (buffer A), followed by incubation for 3 h with 125I-
apoE-VLDL (2 µg/ml) or 125I-α2M (1 µg/ml) at 4°C in the
absence or presence of the indicated unlabeled competi-
tors. 125I-ligands were diluted into buffer A containing 1%
BSA and chilled to 4°C before adding to cells. Unbound
125I-ligand was removed by rinsing cells three times with
cold buffer A after which cells with bound ligand were sol-
ubilized with 0.1 N NaOH. Solubilized proteins were
added to EcoLume (ICN Biomedicals, Costa Mesa, CA)
and subjected to scintillation counting (73% efficiency for
125Iodine). Results were normalized to total cellular pro-
tein (BCA Protein Assay, Pierce, Rockford, IL). Specificity
was determined as the difference between total binding
(without competition) and non-specific binding (non-
competable) [61]. The actual amount of ligand bound to
cells was calculated as cpm ÷ the specific activity of 125I-
labeled ligand. All data points represent averages of repli-
cate points with standard errors of < 5%.
37°C ligand degradation assay
Cells were incubated at 37°C/5% CO2 with 125I-α2M (1
µg/ml) diluted into MEM-Eagle's containing 1% BSA in
the absence or presence of unlabeled α2M (10 µg/ml). At
the indicated times, media was removed and processed
for trichloroacetic acid (TCA) precipitation [62]. TCA sol-
uble material was added to EcoLume and subjected to
scintillation counting. Degradation was calculated as
TCA-soluble cpm ÷ specific activity of the 125I-α2M.
pMH/Syn-1-HA construction and GM00701 cell 
transfections
The cDNA for full length human Syn-1 was obtained from
the I.M.A.G.E. Consortium (clone no. 3347793 in pOTB7
vector, accession no. BE272506) and amplified by PCR
using the following conditions: 30 cycles, 94°C for 1 min,
60°C for 1 min, 72°C for 3 min; 1 cycle, 72°C for 7 min.
Primer sequences used: upstream, 5'-CCGGGCAGCAT-
GGGGCGCGCG-3'; downstream, 5'-TTGGCATAGAAT-
TCCTCCTGTTTGG-3'. The cDNA was cloned into pMH
vector (Roche, Indianapolis, IN) using restriction sites
HindIII and Not1, and placed in frame with a hemagglu-
tinin (HA) peptide-encoding sequence at its 3' end. pMH/
Syn-1-HA vector was introduced into DH5α E. coli,
amplified by overnight growth, and purified for mamma-
lian transfections using an endotoxin-free plasmid purifi-
cation kit (Qiagen, Valencia, CA). For transfections,
GM00701 cells were plated onto 10 cm tissue culture
dishes and incubated with 8 µg vector/dish together withLipids in Health and Disease 2006, 5:23 http://www.lipidworld.com/content/5/1/23
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Lipofectamine Plus according to the manufacturer's
instructions (Invitrogen, Carlsbad, CA). Forty eight hours
post-transfection, cell growth media was replaced with
fresh media containing 1 mg/ml neomycin for selection
of stably transfected cells.
Anti-Syn-1 polyclonal antibody
The cDNA for full length human Syn-1 was amplified by
PCR using the conditions described above and cloned
into pET28 vector (EMD Biosciences, San Diego, CA)
using restriction sites HindIII and XhoI. The cDNA was
placed in frame with a hexa-histidine encoding sequence
at its 3' end (Syn-1-His6). Primer sequences used:
upstream, 5'-GCAAGCTTCAAATTGTGGCTACTAATTT-
GCCC-3'; downstream, 5'-CGCTCGAGGGCATAGAATTC-
CTCCTGTTTGG-3'. Syn-1-His6  was purified by nickel-
affinity chromatography and purity (> 95%) was con-
firmed by Coomassie staining following SDS-PAGE. Pro-
tein identity was also confirmed by mass spectrometry
analysis (University of New Mexico Proteomics Core
Facility). Purified Syn-1-His6 (500  µg) was thoroughly
mixed with an equal volume of Freund's Complete adju-
vant and injected subcutaneously into New Zealand
White rabbits. Rabbits were boosted with 100 µg Syn-1-
His6 mixed with Freund's Incomplete adjuvant at three
week intervals.
Preparation of Di-I-labeled apoE-VLDL
New Zealand White rabbits were placed on a high-fat
chow diet (10% peanut oil/1% cholesterol) for a mini-
mum of 4 d, blood was drawn into 1 mM EDTA and cen-
trifuged at 2000 × g, 15 min to remove cells.
Chylomicrons were floated by centrifuging plasma at
100,000 × g for 10 min and removed by pipetting. Plasma
was then mixed with OptiPrep™ (12% iodixanol final
concentration, Oslo, Norway) and centrifuged at 350,000
× g for 20 h (SW55Ti rotor) with slow acceleration and
deceleration. VLDL particles (density of 1.006 g/ml) were
removed from the top of the gradient by pipetting and
analyzed by SDS-PAGE and Coomassie R staining to con-
firm the presence of apoB100 (Mr, 512 kDa) and apoE
(Mr, 34 kDa). Animal protocol (#0350) was approved by
the University of New Mexico, Health Sciences Center
Laboratory Animal Care and Use Committee. For DiI
(3,3'-dioctadecylindocarbocyanine, Molecular Probes,
Invitrogen) labeling, a working stock of 3 mg/ml was
made in dimethylsulfoxide and 0.15 mg was slowly added
to 1.67 mg apoE-VLDL (in 1.9 ml) with vortexing to rap-
idly mix. The mixture was then wrapped in foil and incu-
bated for 8 h at 37°C. Unincorporated DiI was removed
from DiI-labeled apoE-VLDL by OptiPrep™ gradient cen-
trifugation as described above.
DiI-labeled apoE-VLDL uptake assay
GM00701 or GM00701/Syn-1-HA cells were plated on
glass coverslips, rinsed twice with MEM-Eagle's and incu-
bated with DiI-apoE-VLDL (4 µg/ml) diluted into MEM-
Eagle's containing 1% bovine serum albumin in the
absence or presence of heparin (200 µg/ml) or RAP-GST
(50 µg/ml). After 1 h at 37°C, cells were rinsed with phos-
phate buffered saline, fixed with 3% (w/v) paraformalde-
hyde for 20 min, and mounted using Vectashield (Vector
Labs, Burlingame, CA). Cells were observed with a Zeiss
Axioskop microscope equipped for epifluorescence.
Images were capture with a Hamamatsu digital/video
camera and AxioVision software.
K+ depletion studies
K+ depletion studies were carried out according to Larkin,
et al. [42]. Briefly, GM00701/Syn-1-HA cells were rinsed
with K+-free buffer (50 mM Hepes, pH 7.4, 100 mM NaCl)
and subjected to hypotonic shock by incubation at 37°C
for 5 min with a 1:1 ratio of MEM-Eagle's media:dH2O.
Hypotonic shock buffer was then replaced with K+-free
buffer for 10 min at 37°C. Control, non-treated cells were
incubated in parallel with serum-free, MEM-Eagle's
media. Cells were then incubated at 37°C with either 125I-
apoE-VLDL or 125I-α2M diluted into K+-free buffer (treated
cells) or serum-free, MEM-Eagle's media (control cells). At
the indicated times, cells were chilled on ice and rinsed
(3X) with ice cold 20 mM Hepes, pH 7.4, 150 mM NaCl.
Bound ligand that had not undergone internalization was
dissociated by a 5 min incubation with 20 mM NaOAc,
pH 3, 150 mM NaCl. Internalized 125I-ligand was then
extracted by solubilizing cells with 0.1 N NaOH, added to
EcoLume and quantitated by scintillation counting. In all
cases, specificity of ligand internalization was determined
by a parallel co-incubation with > 10-fold molar excess of
unlabeled ligand.
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